Introduction
Medication adherence can be defined as the extent to which one's medication-taking behaviour follows that mutually agreed upon by the prescribing physician. [1] Optimal adherence is often deemed crucial for the success of a patient's treatment, [2] as suboptimal adherence may lead to treatment failure [3] and unnecessary medical expenditure. [4] It has been estimated that adherence to chronic disease medications is as low as 50% among the general population in developed countries. [1] Adherence is a dynamic phenomenon and can vary with time. [5] The interplay of five main factors may influence adherence: disease-related factors (e.g. lack of disease symptoms); medications (e.g. regimen complexity); the health care system (e.g. access to health services); the patient (e.g. disease and medication knowledge); and socio-economic factors (e.g. education level). [1, 5] Non-adherence can be subcategorised into intentional or non-intentional, [1, 5] with the former being a deliberate action, while the latter results from an individual's inability to take their medications (due to, for example forgetfulness or misunderstanding medication instructions). [1] An ever-growing volume of international evidence has highlighted the positive contribution community pharmacists can have on improving patients' medication adherence and health outcomes, [6] primarily through the provision of pharmaceutical care interventions. [1] Pharmaceutical care interventions aim to promote a patient's quality of life through the provision of responsible drug therapy services. [1, 7] Community pharmacists have detailed knowledge about disease prevention and management, and this positions them ideally within the primary health care system to provide pharmaceutical care interventions. [8, 9] Additionally, they are one of the most accessible health care providers to the public [9, 10] and have regular contact with those with long-term health conditions and those in poorer health. [10] Their regular patient contact provides community pharmacists with many opportunities to identify and follow up on patients' adherence issues. This regular contact also enables rapport to be established and a trusting therapeutic relationship to be fostered, between the pharmacist and the patient. Recently, role expansions for community pharmacists have driven a change in their workplace duties, away from predominately dispensing to encompass more patientcentred roles and the provision of pharmaceutical care. [7] This systematic review summarises the available literature exploring the impact of community pharmacist-led interventions on patients' medication adherence and other health outcomes. To date, pharmacy interventions have been provided in a variety of health care settings, such as primary care clinics, ambulatory centres and community pharmacies. There is reason to believe that the effectiveness of interventions may differ among the various settings, partially due to different barriers to intervention implementation. [8] In community pharmacy, for example, access to patients' clinical information is limited, and the dispensing process generally drives pharmacy workflow. [8] A review conducted by Blalock et al. [8] found that the evidence supporting the positive impact of community pharmacy-based interventions on patients' health outcomes and medication adherence is still limited, when compared to other health care settings. The review by Blalock et al. [8] was limited to studies published in the USA, until December 2011. Consequently this review is an update, while also encompassing studies published worldwide. The focus will be solely on the community pharmacy setting.
This systematic review will address the following research questions: What disease states and health issues are community pharmacist-led interventions targeting and what is the impact of these interventions on patients' medication adherence and clinical, humanistic, economic and/or other health outcomes? The findings will provide a general overview of the types of interventions that have been implemented in the community pharmacy setting and their effectiveness.
Methods to assess adherence are plentiful in the literature. This review will include studies using objective measures of medication adherence, such as pill counts, pharmacy refill records and electronic monitoring devices, as well as validated self-report scales, or both. A comparison of the validity of the different adherence measures is beyond the scope of this review.
Methods

Search strategy
A systematic literature search was conducted to identify articles with information about community pharmacistled interventions. Refer to Table S1 for details on the inclusion and exclusion criteria used. Medline, EMBASE, International Pharmaceutical Abstracts, ProQuest Dissertations and Theses and Google Scholar databases were searched for English, peer-reviewed articles. The search was undertaken in October 2015, and all articles published until October 2015 were included. The literature search strategy was developed in consultation with a subject librarian. Keywords for the literature search were informed by the study by Blalock et al. [8] The search terms used for the Medline (Ovid) search were: [ The search terms were combined using Boolean operators, and no language or publication date limits were applied to the database searches. In addition, the reference lists of systematic reviews were scanned for potentially relevant articles. Only articles published in English were included in the final review.
Article selection
The titles of all retrieved articles were independently screened for eligibility by two authors (AM and TA). Abstracts were then screened when the title of the article appeared relevant. This was undertaken by two authors (AM and TA). Full texts were obtained for all the relevant articles published in English. The full texts were read by two authors (AM and TA). When doubt arose regarding article eligibility, the full text was obtained and discussed amongst all the authors (AM, TA and JH). Two of the authors (AM and TA) independently read all the final articles for the systematic review to ensure all articles met the inclusion criteria. The inclusion and exclusion criteria are summarised in Table S1 . Duplicate articles were removed using RefWorks software.
Data extraction
A data extraction form was developed, and relevant data from eligible articles was extracted by AM. The data extraction form contained the following fields: study design, setting (e.g. community pharmacy), intervention details (e.g. disease state being targeted, pharmacist training undertaken, type of intervention, frequency of pharmacist-patient visits), outcomes (e.g. behavioural, clinical and/or humanistic and/or economic), participant characteristics (e.g. demographics, participant inclusion and exclusion criteria) and analysis undertaken (e.g. per-protocol).
Quality appraisal and data analysis
A risk of bias assessment was conducted for each of the included articles using Cochrane guidelines. [11] Selection, performance, detection, attrition and reporting biases were examined. The risks were expressed as 'low risk', 'high risk' and 'unclear risk'. Articles where most of the domains were "high risk" were discussed amongst the authors to ensure appropriateness of the classification and to justify their inclusion in the final review. Additionally studies were compared based on their study design, the interventions undertaken and their findings. Pooling of the results to undertake meta-analysis was inappropriate as the study populations, interventions and methods of estimating adherence varied between the studies.
Results
Overview
The database search yielded 977 articles, with an additional 37 articles being identified from other sources. Duplicate articles were removed, and screening for eligibility was conducted independently by AM and TA, who read the study titles of all 875 articles retrieved. The abstracts were read when eligibility from the title was unclear, and after screening, a total of 22 studies remained. After reading the 22 studies, it was found that three of the studies had more than one article published about the study (i.e. different outcomes reported in different journal articles). These articles were also identified from the full text and included in this systematic review. Thus, in this systematic review 22 studies, reported in 26 peer-reviewed journal articles, were included in the qualitative synthesis. Refer to Figure 1 for details on the article selection process.
The studies were published from 1973 to 2015, and the majority were randomised controlled trials (n = 16). Most of the studies (n = 8) were from USA, followed by Australia, Belgium and the Netherlands (n = 3 each). Hypertension was the most frequently targeted health condition (n = 9), with diabetes, asthma and depression being discussed equally (n = 3). Each study included in the review assessed medication adherence as an outcome, with pharmacy dispensing records (n = 9) being the main measure used, and five studies used both pharmacy dispensing records and a self-report tool for their adherence estimates. Table S2 summarises the characteristics of the studies included in the final review.
Risk of bias assessment
The quality of all eligible studies was examined against each of the following criteria: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment for each outcome, incomplete outcome data and selective reporting. One study identified during the literature search was omitted from this review even though it met the inclusion criteria. It was deemed poor quality by two of the authors, due to the small sample size (n = 8), and the limited reporting of the study outcomes and their statistical significance. [12] Blinding of participants and personnel was a domain that was frequently identified as being at 'high risk' of bias in the eligible studies. Often the community pharmacist provided the intervention and also assessed the outcome (particularly clinical outcomes such as measurement of blood pressure (BP) and cholesterol levels in the pharmacy, or administering questionnaires to patients, either for self-reported adherence or assessing depression control). This may in part be due to the nature of the interventions conducted by these pharmacists, which were education-based. Patients were often unblinded and aware of their allocation into the intervention or control groups. Since all studies provided patients with information before participating, patients could easily determine this allocation and would have known their adherence and/or clinical outcome was going to be assessed.
Qualitative synthesis of outcomes
The studies included in this review assessed the impact of community pharmacist-led interventions on patients' medication adherence and other health outcomes. The outcomes described in these studies included: behavioural, clinical, humanistic and economic outcomes. Refer to Table S3 for a summary of the study outcomes and their statistical significance.
Behavioural outcome (medication adherence)
Measurement methods
All eligible studies evaluated the impact of a community pharmacist-led intervention on patients' medication adherence (n = 22). The tools used to assess adherence varied between the studies. Twelve studies used objective measures to estimate adherence (pharmacy dispensing records, pill counts or electronic pill counter, or MEMS), [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] while five studies relied solely on validated self-report adherence tools. [27] [28] [29] [30] [31] [32] The Morisky scale [28] was the most frequently used self-report adherence tool. Five studies used two adherence measures, an objective measure (primarily dispensing records) and a self-report tool. [33] [34] [35] [36] [37] [38] [39] Using more than one adherence method was often done in an attempt to validate the authors' results. Mehuys et al. [34] found a significant difference in adherence rates between the intervention and control patients using dispensing records yet when assessed using a selfreport tool, there was no significant difference in the same cohort. Sturgess et al. [35] assessed change in percentage of patients' adherent to treatment using self-report and dispensing records. Using the self-report tool, they found a significantly higher proportion of intervention patients compared to control patients changed from being non-adherent to adherent by the end of the study. However, when adherence was assessed using the prescription Some studies were reported in more than one journal article. These additional articles were also included in this review. [Color figure can be viewed at wileyonlinelibrary.com] records the difference between the two groups disappeared. These two studies suggest a lack of concordance between self-reported and objective adherence measures.
Changes reported
A total of 65 adherence outcomes were reported for the 22 studies, with 61.5% of the outcomes showing a statistically significant result (p < 0.05), favouring the intervention group. Eleven studies reported the percentage of patients' adherent to treatment as an outcome. [13, 16, 23, 26, 29, [31] [32] [33] 35, 36, 39] In six of these studies, a significantly higher proportion of intervention cohorts were adherent to their medications after the intervention, compared with control groups. [13, 16, 26, 32, 35, 39] One study found no statistically significant differences, [36] and four other studies did not report on the statistical significance of their results. [23, 29, 31, 33] Of the 11 studies reporting on the percentage of adherent patients, the majority specified a cut-off point that classified adherent and non-adherent patients. [13, 16, 23, 26, 29, 31, 32, 36, 39] The studies using pharmacy records to estimate adherence primarily used 80% as the cut-off value for defining patients as adherent or nonadherent. [13, 16, 26] Twelve studies reported patients' mean adherence rates. [13, 14, 20, 21, 23, [25] [26] [27] 31, 34, 36, 39] Of these, three studies reported a statistically significant difference in the mean adherence rate between the intervention and control groups, favouring the intervention. [13, 25, 39] Four studies found a non-significant difference in mean adherence rates between the intervention and control groups. [14, 21, 26, 36] One study did not report on the statistical significance of their findings, [23] while another study found no effect of the intervention on the mean adherence rate between intervention and control patients. [27] Two studies reported contradictory findings in their mean adherence rates between the intervention and control groups. [20, 34] Clinical outcomes
Blood pressure
Ten studies in the review used BP measurements as a clinical outcome to assess the effectiveness of their intervention. The BP outcomes from these studies were reported in 12 journal articles. [16, 20, 21, 23, 25, 29, 31, 32, [36] [37] [38] [39] The proportion of patients reaching their goal BP was assessed in six studies. [16, 20, 21, 23, 31, 39] Three studies found a significantly greater proportion of patients achieved their goal BP in the intervention group compared with the control group. [21, 23, 39] Two studies found no significant differences in the proportion of patients reaching their goal BP, [16, 31] while one study did not report the significance of the observed differences between the intervention and control groups. [20] Target BPs varied between the studies; Planas et al. [21] used a goal BP of <130/ 80 mmHg, while Svarstad et al. [16] and Robinson et al. [20] used <140/90 mmHg. A more lenient goal of <159/ 89 mmHg was used by Blenkinsopp et al. [39] Five studies assessed the effect of the intervention on patients' systolic BP (SBP), by comparing SBP between the intervention and control patients. [16, 20, 21, 31, 36] Four studies found a significantly greater reduction in SBP in the intervention groups compared with the control groups. [16, 20, 21, 36] One study found a non-significant difference between the intervention and control groups. [31] HbA1c and blood glucose levels Three studies described the impact of community pharmacist-led interventions on patients' glycated haemoglobin (HbA1c) [26, 29, 33] and on blood glucose levels. [33] Two studies were randomized controlled trials (RCTs), [29, 33] and one was a retrospective cohort study. [26] They were conducted in Belgium, [33] the USA [26] and Iran. [29] The findings regarding the interventions' impact on mean HbA1c were mixed; with one study reporting a significant difference in mean HbA1c levels, favouring the intervention group, [26] while for the remaining two studies the differences were not statistically significant. Although Jahangard-Rafsanjani et al. [29] found no significant difference in their main analysis, they did report a significant reduction in HbA1c in the intervention groups compared to the controls, when they undertook subanalysis of patients with a low baseline HbA1c (<7%). Mehuys et al. [33] also examined the impact of the intervention on mean fasting blood glucose (FBG) levels and found no significant difference between groups at the end of the study period (6 months); however, 18 months after this period the mean FBG level in the intervention group was significantly lower than in the control group.
Blood lipids and cholesterol levels
Two studies reported on the impact of community pharmacist-led interventions on patients' cholesterol levels. [26, 27] The first study was an RCT conducted in Australia, [27] while the second study involved a retrospective cohort and was conducted in the USA. [26] Aslani et al. [27] found the intervention group significantly lowered their non-fasting cholesterol levels over the study period, while the control group did not. Spence et al. [26] focused on low density lipoprotein cholesterol (LDL-C) and found a significant difference in mean LDL-C levels between the intervention and control groups, favouring the intervention arm.
Respiratory disease control
Four studies described the impact of interventions on either asthma or chronic obstructive pulmonary disease (COPD) control, or both conditions. [13, 24, 30, 34] The outcomes reported in these four studies varied greatly. Ottenbros et al. [24] used the prescribing of HDT (oral High Dosage Therapy (corticosteroids or antibiotics)) as a proxy measure of asthma/COPD control, and they did not report the statistical significance of the differences between the intervention and control groups. Mehuys et al. [34] and Armour et al. [30] explored asthma control, using different outcome assessments. Mehuys et al. [34] found improvements in Asthma Control Test score in patients with insufficiently controlled asthma at baseline, as well as a significant decrease in night time awakening in the intervention group compared to the control group. Compared to baseline, intervention patients also showed significantly decreased use of rescue medications during and at the end of the study period. [34] Armour et al. [30] found that the proportion of intervention patients with severe asthma significantly declined during the study, while the proportion in the control group did not change significantly. However, no significant changes were found in FEV 1 and FEV 1 /FVC from baseline to the end of the study in both groups. [30] Tommelein et al. [13] explored COPD control and found a significantly lower frequency of severe exacerbations in the intervention group compared with the control group. The estimated annual rates of severe exacerbations were found to be significantly lower in the intervention group compared to the control group. A nonsignificant difference was reported between the groups for moderate exacerbations.
Symptoms of depression
Depressive symptom control was evaluated in three studies. [14, 18, 19] Each study used a different assessment tool, the Beck Depression Inventory-II, [19] Patient Health Questionnaire (PHQ-9) [18] and the Hopkins Symptom Checklist (SCL-13). [14] However, none of the studies found a significant difference in depressive symptom control between the intervention and control groups at the end of the study period.
Other clinical outcomes
Hospital visits
Six studies reported the effect of the intervention on patient hospitalisation rates. [13, 22, 26, 31, 34, 35] A total of 13 outcomes were reported. Only three of these outcomes showed statistically significant differences between the intervention and control groups. In the diabetic cohort, Spence et al. [26] found the percentage of patients visiting the emergency department was significantly lower in the intervention group compared with the control group. Similarly, Tommelein et al. [13] found a significant reduction in the annual hospitalisation rate (rate ratio: 0.28, p=0.03), as well as the number of hospitalisation days in the intervention group (rate ratio: 0.27, p<0.0001), compared to the control group.
Intensification or change to treatment
Six studies described the impact of community pharmacist-led interventions on patients' treatment regimens. [16, [29] [30] [31] 33, 35] The outcome measures varied greatly amongst these studies (see Table S3 for more details).
Humanistic outcomes
Knowledge about medication and/or illness
Patients' knowledge about their medications and/or their illness was explored in six studies. [19, 23, 30, [33] [34] [35] Three studies reported significantly greater patient knowledge in the intervention groups at the end of the study period, when compared with the control groups. [19, 23, 30] Patient satisfaction Six studies reported on the impact of the intervention on patients' satisfaction levels. [15, 16, 18, 29, 35, 39] All of the six studies reported on patient satisfaction with the particular intervention, while some also incorporated satisfaction with general pharmacy services as well. [29, 39] In four studies, intervention patients reported being satisfied with community pharmacists' services provided to them. [15, 16, 29, 35] Rubio-Valera et al. [18] did not find a difference in terms of patient satisfaction between the intervention and control groups, while Blenkinsopp et al. [39] reported a non-significant difference.
Quality of life
Eight studies investigated changes in patients' quality of life as a result of the community pharmacist-led interventions. [13, 18, 20, 22, 25, 30, 34, 35] Four studies used generic quality of life assessment tools: SF-36, [20, 35] SF-12, [25] EuroQol, [18] while two studies used a generic tool together with a disease-specific tool. [13, 22] Mehuys et al. [34] and Armour et al. [30] used a disease-specific tool, the Asthma Quality of Life Questionnaire, to assess the quality of life in those with asthma. The tools used varied greatly between the studies as did the results, making comparisons difficult (see Table S3 for more details).
Economic outcomes
Four studies evaluated the impact of the pharmacist-led interventions in terms of their economic benefit. [14, 17, 26, 35] Studies by Rubio-Valera et al. [17] and Bosmans et al. [14] targeted depression symptom control, and both studies undertook a cost-effectiveness analysis. The first study, an RCT conducted in Spain, found the intervention was unlikely to be cost-effective compared to the control group in terms of improving depression symptoms. [17] Bosmans et al. [14] also carried out an RCT and assessed their intervention cost-effectiveness in terms of improving adherence. They reported that the intervention was likely to be cost-effective. [14] The remaining two studies targeted diabetes control [26] and older people's health. [35] Spence et al. [26] found that their intervention had the potential to reduce costs associated with ED visits and hospitalisations while providing a positive Return on Investment of 5.74 (USD) for every dollar spent on the intervention. Sturgess et al. [35] on the other hand found no significant difference in the cost of health care (per patient) between the intervention and control groups, or any significant difference in medication costs.
Discussion
This review found that community pharmacist-led interventions can improve patients' adherence to medications and can contribute to better BP control, cholesterol management, COPD and asthma control. However, the findings did not report statistically significant effects of the interventions on glycated haemoglobin (HbA1c) levels or depression symptom control.
When interpreting the results from this review, several caveats need to be considered. Only studies published in English were reviewed, and it is possible that there were more studies published in other languages that have not been reported. One member of the research team was involved in data extraction, and this is a possible limitation of this review. Some of the reviewed studies were observational studies; Roebuck et al. [4] noted that observational studies are often at risk of biases, as an unobserved confounder can influence both the groups being compared and the outcome that is being assessed. However, since this review aimed to provide a general overview of all the studies available in this area, exclusion of these observational studies would have been inappropriate. Furthermore, this review only analysed community pharmacist-led interventions and interventions often had several components, and this made it difficult to ascertain which particular component of the interventions contributed to the improvements observed. [26, 31, 33] Future studies should attempt to identify which aspects of the intervention have the greatest impact on their desired health outcomes, in their particular cohort. This may include, but should not be limited to, the contribution of multicompartment adherence aids and refill reminders, in improving patient health outcomes. Most of the reviewed studies were unblinded, and usually both patients and pharmacists volunteered to participate in the studies. [31] There may be systematic differences between patients and pharmacies who voluntarily participate compared to those who do not. Additionally, some of the reviewed studies lacked details about the intervention procedures, such as the nature of the intervention and the individuals involved in data collection. For example, one study explored the impact of a 1-month pharmacist-led intervention on heart failure control; however, details on how the intervention was delivered was not provided (e.g. face-toface intervention or through telephone). [22] This makes comparisons across studies challenging. Attempts to contact authors did not occur, and only the information provided in the journal articles was used in the analysis.
Behavioural outcome (medication adherence)
All the studies in this systematic review evaluated the impact of a community pharmacist-led intervention on patients' medication adherence. A total of 65 outcomes were reported, and nearly two-thirds of the outcomes (61.5%) showed a statistically significant result, favouring the intervention group. This is higher than the overall figure reported by Blalock et al. [8] who reported a significant difference in 43.3% of the studies used. However, the two reviews are different in terms of the types and number of studies, the countries studied and the outcomes reported.
The tools used to estimate adherence in this systematic review vary greatly, with objective measures being most frequently used. Fewer studies relied solely on validated selfreport adherence tools, and others used both objective measures (primarily pharmacy records) and self-report tools. These authors often used more than one adherence tool, in an attempt to validate their results. This is worthwhile, as a review by Van Wijk et al. [40] reported differences in adherence rates using the different adherence tools. [40] This was also evidenced in certain studies included in this review, whereby different adherence tools yielded different adherence values. [34, 35] It is possible that certain tools are insensitive and thus unable to accurately capture small changes in adherence behaviours in particular study cohorts. Aslani et al. [27] suggested that this may have been the case in their study, when they were unable to detect any difference in non-adherence between the intervention and control groups using the MARS self-report tool. [27] International Journal of Pharmacy Practice 2018, 26, pp. 387--397 © 2018 Royal Pharmaceutical Society
Clinical outcomes
Cardiovascular disease is the leading cause of death in many countries, burdening both patients and society. Improving the management of, and targeting the risk factors for, cardiovascular disease are consequently important goals. [41] Diabetes for example, is a major risk factor for kidney failure and stroke and has been previously described as a contributor to both blindness and lower extremity amputations, [42] while affecting on average 5% of Australians [41] and 7.8% of Americans. [43] Due the negative consequences and prevalence of this disease, it is somewhat disappointing to see community pharmacistled interventions, in this systematic review, had little impact on patients' diabetes control. This contradicts other diabetes interventions; for example, in a study by Krass et al., [44] they found positive benefits from a pharmacist-led diabetes intervention on patients' HbA1c and blood sugar control. However, the study by Krass and colleagues did not estimate adherence as an outcome and it consequently did not meet the inclusion criteria for this systematic review. [44] Blalock et al. [8] also reported positive effects of community pharmacist-led diabetes interventions on patients' diabetes management; however, those diabetes studies in Blalock's review had generally weak study designs. The current review included three studies exploring diabetes management, [26, 29, 33] with one being underpowered, [29] thus limiting our ability to draw fully informed conclusions. Nonetheless, it was interesting to see the importance of patients' baseline characteristics in the diabetes interventions. It was noted that patients with poorer glycaemic control [33] and those deemed nonadherent at baseline [26] had the potential to benefit most from the diabetes interventions.
Reductions in BP have been associated with lower cardiovascular morbidity and death rates, as well as lower numbers of strokes and coronary events. [45] It is promising to see the large number of community pharmacist-led interventions targeting hypertension, and the significant contribution pharmacists can have in managing this condition. This is possibly because hypertension can be easily monitored in the community pharmacy setting by measuring a patient's BP. [39] Most hypertension interventions aimed for patients to reach a target BP; however, these targets varied often by country, by comorbid disease states and the year that the studies were undertaken. For example, Blenkinsopp et al. [39] used targets applicable to the 1998 setting, which described uncontrolled BP as >159 mmHg systolic and/or >89 mmHg diastolic readings. In more recent studies, the targets are stricter with many reporting target BPs as 130/80 or 140/ 90 mmHg. Six studies assessed the proportion of patients reaching their goal BP, [16, 20, 21, 23, 31, 39] and in half the studies, a significantly greater proportion of intervention patients achieved their goal BP, compared with control patients. [21, 23, 39] The interventions
The most effective interventions to improve adherence are multifaceted, [46] targeted and personalised. [47] They usually have a combination of components including education, simplification of treatment regimens, communication between patients and their health care professionals, follow-up and monitoring. [46] Most of the interventions assessed in this review focussed on patient education and/ or counselling, as well as other components; thus, they were multifaceted. This finding is in line with another study. [48] Thoopputra et al. [48] classified interventions into patient-orientated and professional interventions (including medication review and referral), and they identified more than half (53%) as patient orientated focussing on patient education, counselling, monitoring and risk screening. They found fewer studies involved both patient and professional interventions (44%). In the current systematic review, most studies involved a component of patient education or counselling. The focus was primarily on patients' medications, medical conditions and demonstration of effective technique (for example inhaler technique). Educational interventions are easy to implement in the community pharmacy setting, while being relatively low cost and effective among different participant groups. [9] They can also positively influence patient satisfaction and knowledge, [49] because patients generally desire greater information about their therapies. [39] The findings from this systematic review align with this notion, as the pharmacist-led interventions positively influenced patients' satisfaction and knowledge.
Most of the reviewed studies were randomised controlled trials, and the randomisation process was mostly done at the pharmacy level. This could be due to authors attempting to minimise contamination (by control patients accidentally receiving the intervention), practicality issues associated with altering consultations between patients or due to potential ethical issues. [39] Some studies selectively recruited patients, and this may have contributed to selection biases. Blenkinsopp et al. [39] reported that a small number of pharmacists intentionally excluded certain patients from participation, with the reasons for this selective recruitment not being specified: perhaps recruiting regular patients more frequently, and avoiding those with whom they lacked rapport.
Barriers to implementation of community pharmacistled interventions have been described previously, and they include but are not limited to, lack of time, training, resources, interprofessional relationships and collaboration and lack of public awareness of available services. [10] The timing of the intervention can also play an important role in its success. Eussen et al. [9] suggested that patients newly starting statin treatment may be most likely to benefit from the pharmaceutical care interventions during the initial months, as adherence levels usually decline several months after beginning treatment. [9] Although this example pertains to statin initiation, similar findings have been found for hypertension medications too, with 50% of patients' stopping antihypertensive treatment one year after commencement. [50] Another time component to consider is the duration of the intervention itself, as a review conducted by van Dalem et al. [51] found intervention duration can impact adherence intervention effectiveness in patients with cardiovascular disease. [51] Furthermore, pharmacists have been reported as being their own barrier to successful pharmaceutical care, with many finding extended pharmacy interventions too overwhelming to implement. [39] Zillich et al. [31] found that not all pharmacists are equally assertive, and certain pharmacists did not recommend changes to patient therapy, possibly as a result of this assertiveness. A potential solution is further pharmacist training, policy development as described by Mossialos et al. [52] and providing sufficient remuneration for services provided. This would help ensure that pharmacists are sufficiently skilled, motivated and confident in providing new services, and are appropriately rewarded for their work. [52] Another barrier that is important to consider is the transferability of interventions to other community pharmacy settings. Zillich et al. [31] reported that their high intensity intervention may not be suitable for all community pharmacies to implement due to the high workload and time intensive nature of their intervention. Chabot et al. [53] also raised this concern. They found that for their high intensity interventions pharmacists spent approximately 100 minutes per patient, compared to the low intensity interventions where pharmacists spent less than 15 minutes per patient. It is possible that patient consultations by appointment are needed for successful implementation of certain interventions. [53] Quality of included articles
The risk of bias assessment indicated that many of the reviewed studies were biased in the performance bias domain, whereby blinding of either participants or pharmacists did not occur. The community pharmacist often delivered the intervention and also assessed the outcomes. However, often the outcome was assessed using an objective measurement tool, which may have minimised the potential effects of this bias on the outcome (e.g. a blood test to assess cholesterol, refill records to assess adherence or BP readings to assess hypertension control). Some studies involved personnel other than the pharmacist to measure the clinical outcomes. [14, 15, [17] [18] [19] 34, 35] This may help mitigate bias related to lack of blinding and may be worthwhile adopting in future similar studies.
Another domain often assessed as 'high risk' in the studies included in this review was selection bias, as concealment of patient allocation was rarely undertaken. This could have given rise to the Hawthorne effect which sees patients' behaviours change as a result of knowing they are being observed or assessed, leading to them behaving in a socially desirable manner. [33, 54] This is particularly an issue for patients in the control group, as improvements in their outcomes may occur by them merely participating in the study. This has potential to mask the full effect of an intervention. [33] 
Conclusion
Community pharmacist-led interventions have contributed to improved medication adherence and better disease control. Particularly, they have contributed to better BP control, cholesterol management, COPD and asthma control. The studies in this review, however, did not find an effect of the interventions on glycated haemoglobin (HbA1c) levels or depressive symptom control.
Most of the interventions were delivered face-to-face and involved an educational component, to improve patients' understanding of their medications or illnesses. While literature is already available to support the use of educational interventions in the community setting, understanding the contribution of the other intervention components is also important. Future research should attempt to better understand which components make the greatest contribution towards improving adherence and health outcomes, for patients with different medical conditions.
